This article is more than 5 years old. Information may no longer be current.
Intravitreal Avastin shows potential for treating neovascular glaucoma
Click Here to Manage Email Alerts
Intravitreal bevacizumab may be an effective adjunctive treatment for patients with neovascular glaucoma, a case series suggests. The treatment leads to rapid regression of iris and angle neovascularization in eyes with neovascular glaucoma caused by central retinal vein occlusion, the authors of the case series said.
Milko E. Iliev, MD, and colleagues at the University of Bern in Switzerland reviewed their outcomes in six consecutive patients treated with intravitreal bevacizumab for neovascular glaucoma caused by CRVO. All patients had refractory elevation in IOP and pronounced anterior segment congestion, according to the study authors.
By 48 hours' follow-up, all patients showed relief from symptoms and a dramatic regression of anterior segment neovascularization. IOP decreased substantially in three eyes; the other three eyes required adjuvant cyclophotocoagulation.
No patients had evidence of any adverse effects to the treatment, the authors said.
The study is published in the December issue of the American Journal of Ophthalmology.